Compare ELTX & CMTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTX | CMTL |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | United States | United States |
| Employees | N/A | 817 |
| Industry | Biotechnology: Pharmaceutical Preparations | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 52.7M |
| IPO Year | 2014 | 2024 |
| Metric | ELTX | CMTL |
|---|---|---|
| Price | $1.52 | $1.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $13.00 | $3.63 |
| AVG Volume (30 Days) | ★ 305.0K | 248.1K |
| Earning Date | 11-05-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 39.29 | ★ 66.76 |
| EPS | ★ N/A | N/A |
| Revenue | $2,301,000.00 | ★ $249,613,000.00 |
| Revenue This Year | N/A | $6.27 |
| Revenue Next Year | N/A | $4.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.25 | $1.10 |
| 52 Week High | $16.00 | $6.21 |
| Indicator | ELTX | CMTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.97 | 43.63 |
| Support Level | $1.35 | $1.15 |
| Resistance Level | $1.98 | $1.53 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 42.19 | 36.89 |
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.